Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

Abroad (travel likely)RecruitingPHASE2

Conditions

Non-Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Hong Yang, Ph.D.,M.D.) · yanghong@sysucc.org.cn · 008613560405144

Study leads

Hong Yang, Ph.D.,M.D.
Principal Investigator
Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Little Rock, United States · Los Angeles, United States

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Cleveland, United States

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China